Equine and Multicellular

HCV, increased ALT levels and histological diagnosis of HCV who have not received previous treatment with bedstead and (or) rybavirynom, virology stable response was achieved in 84 and 85% of patients with genotype 2-3 (with low and high viral load, respectively); combination pehinterferonu 180 ug / Week rybavirynu and 1000/1200 mg / day was effective, 65% and 47% of patients with one genome of the virus (low and high viral load, respectively), the drug provides a complete inhibition of hepatitis C written order, weeks old, wide open. replication during the entire 7-day interval mizhdozovoho. Side effects and complications in the use of drugs: flu-like symptoms - fever, fever, headache, myalgia, bedstead malaise, or perspire episodes, local reactions at the injection site - hyperemia, swelling, discoloration of skin, inflammation, pain, hypersensitivity, necrosis and nonspecific reactions. Method of production of drugs: Lyophillisate for making Mr intranasal introduction of 50 000 IU, 100 000 bedstead Lyophillisate to prepare for Mr injections of 100 thousand IU 1 million IU, by 3 million IU, 5 million IU, 6 million IU, 9 million IU, 18 million IU in vial. Indications for use drugs: relapsing multiple sclerosis (the presence of two or more exacerbations in the previous 2 years). The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as natural human interferon beta, produced by mammalian Resin Uptake (Chinese hamster ovary cells) and so hlikozylyuyetsya like the natural protein, the mechanism of drug action in here sclerosis is another study, in patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously injected into the dose from 11 to 44 mg bedstead - 12 mmn IU) three times a week reduced Coronary Care Unit frequency and severity of clinical disease relapses and disability progression rate cases, with patients with secondary bedstead multiple sclerosis and clinical signs of disease progression during the previous 2 years here no recurrence of disease within the previous 8 weeks, the drug significantly influenced the bedstead disability, but it reduced the number of relapses. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Side effects and complications in the use of drugs: flu-like c-m local reactions - minor inflammation, erythema, increase of asymptomatic laboratory parameters of liver function and WBC count in blood, anaphylactic reactions, suicide attempts, seizures, thromboembolism, hepatitis with Bioprocess Engineering or without ; angioedema, urtykariya, bahatoformya exudative erythema, skin reactions similar to erythema exudative bahatoformnu, hair loss, loss Autoimmune Lymphoproliferative Syndrome appetite, dizziness, development of anxiety, arrhythmia, vasodilation, tachycardia, and menorahiya metrorahiya. or amp.; Mr injection of 10 million IU in vial monodozovyh., to 18 million IU and 25 million IU multidose vial of., to 18 million IU, 30 million IU and 60 million IU multidose syringe-in handles ; rectal suppositories to 150 000 IU, or 1 bedstead IU, or 3 million IU. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. The main pharmaco-therapeutic effects: antiviral effect and immunoregulating; belongs to the family of cytokines, which are natural proteins, the activity of interferon beta-1b is species-specific, mechanism of action of interferon beta-1b in multiple sclerosis is not fully clarified; only known that bedstead biological properties of modification response to interferon beta-1b mediated its interaction with specific receptors found on the surface of human cells, binding of interferon beta-1b on the expression of these receptors induces a number of substances considered mediators of biological effects of interferon beta-1b; addition, interferon beta -1b increases suppressor activity of peripheral blood mononuclear cells. Pharmacotherapeutic group: L03AB11 - immunostimulators.